Search

Your search keyword '"Brusselle, GG"' showing total 3 results
Start Over Author "Brusselle, GG" Region belgium
3 results on '"Brusselle, GG"'

1. Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects.

Author

Jacobs M, Van Eeckhoutte HP, Wijnant SRA, Janssens W, Joos GF, Brusselle GG, and Bracke KR

Subjects
Angiotensin-Converting Enzyme 2, Belgium, Biomarkers blood, Biopsy, Needle, Cross-Sectional Studies, Female, Humans, Immunohistochemistry, In Vitro Techniques, Linear Models, Male, Multivariate Analysis, Pulmonary Disease, Chronic Obstructive blood, Pulmonary Disease, Chronic Obstructive epidemiology, Real-Time Polymerase Chain Reaction methods, Respiratory Mucosa metabolism, SARS-CoV-2, Sensitivity and Specificity, Smoking blood, Specimen Handling, Statistics, Nonparametric, Betacoronavirus metabolism, Peptidyl-Dipeptidase A metabolism, Pulmonary Disease, Chronic Obstructive pathology, RNA, Messenger blood, Respiratory Mucosa pathology, Smoking epidemiology
Abstract

Competing Interests: Conflict of interest: M. Jacobs has nothing to disclose. Conflict of interest: H.P. Van Eeckhoutte has nothing to disclose. Conflict of interest: S.R.A. Wijnant has nothing to disclose. Conflict of interest: G.F. Joos reports grants from AstraZeneca and Chiesi, personal fees for consultancy from Bayer and Eureca vzw, grants and personal fees for lectures and consultancy from GlaxoSmithKline, personal fees for lectures from Teva, outside the submitted work; all fees were paid to the department. Conflict of interest: W. Janssens reports grants from AstraZeneca and Chiesi. Conflict of interest: G.G. Brusselle reports personal fees for advisory board work and lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva, personal fees for advisory board work from Sanofi, outside the submitted work. Conflict of interest: K.R. Bracke has nothing to disclose.

Published
2020
Full Text
View/download PDF

2. [Optimizing pharmacotherapy in patients with COPD by community-pharmacists: a cost-effectiveness analysis].

Author

van Boven JF, Tommelein E, Boussery K, Mehuys E, Vegter S, Brusselle GG, Rutten-van Mölken MP, and Postma MJ

Subjects
Belgium, Community Pharmacy Services, Cost-Benefit Analysis, Humans, Pharmacists, Pulmonary Disease, Chronic Obstructive complications, Pulmonary Disease, Chronic Obstructive economics, Quality-Adjusted Life Years, Pulmonary Disease, Chronic Obstructive drug therapy
Published
2014

3. Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.

Author

Ilumets H, Rytilä P, Demedts I, Brusselle GG, Sovijärvi A, Myllärniemi M, Sorsa T, and Kinnula VL

Subjects
Adult, Aged, Belgium, Cross-Sectional Studies, Female, Humans, Male, Matrix Metalloproteinases metabolism, Middle Aged, Pulmonary Disease, Chronic Obstructive classification, Tissue Inhibitor of Metalloproteinases analysis, Tissue Inhibitor of Metalloproteinases metabolism, Matrix Metalloproteinases analysis, Pulmonary Disease, Chronic Obstructive physiopathology, Smoking
Abstract

COPD is underdiagnosed and its early assessment is problematic. It has been suggested that symptomatic smokers with normal FEV1/FVC (Stage 0 COPD, GOLD criteria) can develop COPD in the future. Potential early biomarkers in COPD include the matrix metalloproteinases (MMPs). It is not yet known, whether alterations in MMP expression are associated with smoking alone or with the risk of developing COPD. In this cross-sectional study MMP-8, MMP-9 and MMP-12 were determined from induced sputum and plasma by ELISA, immunocytochemistry, zymography, and/or Western blot in non-smokers (n=32), smokers with symptoms (Stage 0, GOLD criteria) (n=23) or without symptoms (n=23). Only MMP-8 differentiated Stage 0 COPD from non-symptomatic smokers (p = 0.02). MMP-9 levels were significantly elevated in the induced sputum of non-symptomatic smokers and Stage 0 COPD (p = 0.01, p < 0.001) compared to non-smokers, but did not differ between the two subgroups of smokers. MMP-12 was higher only at Stage 0 compared to non-smokers (p = 0.04). MMP-8, MMP-9 and MMP-12 immunoreactivity was localized in macrophages and neutrophils, especially in smokers. MMP-8 levels correlated significantly with the small airway flow parameters (MEF50, MEF25) (p = 0.005 and p = 0.0004) and markers of neutrophil activation (myeloperoxidase, lactoferrin). In conclusion MMP-8 may differentiate Stage 0 from healthy smokers.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results